Results 21 to 30 of about 75,705 (253)

Comparison of effectiveness of growth hormone therapy according to disease-causing genes in children with Noonan syndrome [PDF]

Korean Journal of Pediatrics, 2019
Purpose To analyze the growth response to growth hormone (GH) therapy in prepubertal patients with Noonan syndrome (NS) harboring different genetic mutations. Methods Twenty-three patients with prepubertal NS treated at Pusan National University Children’
Kyo Jin Jo, Yoo Mi Kim, Ju Young Yoon, Yeoun Joo Lee, Young Mi Han, Han-Wook Yoo, Hyang-Sook Kim, Chong Kun Cheon   +7 more
doaj   +1 more source

Human growth hormone produced with recombinant DNA technology [PDF]

BIO Web of Conferences
Hormones affect the metabolism by stimulating the genetic apparatus of the cell, activating enzymes and changing the rate of enzymatic reactions. They increase the formation of informative ribonucleic acid, which determines the structure of the protein ...
Mustafakulov Muhammad, Uralov Abdumannon, Ahmedova Sobira, Saidov Zukhriddin   +3 more
doaj   +1 more source

The Separation of Recombinant Human Growth Hormone Variants by UHPLC [PDF]

Journal of Chromatographic Science, 2012
Reversed-phase ultra-high-performance liquid chromatography (RP-UHPLC) was used for the separation of recombinant human growth hormone (rhGH) variants. A bridged ethylene hybrid silica C18 column was used at 37°C. The composition and temperature of the mobile phase were optimized for the separation.
Göran, Karlsson, Kathryn, Eriksson, Annevi, Persson, Håkan, Månsson, Susanne, Söderholm   +4 more
openaire   +2 more sources

Effects of recombinant human growth hormone administration on cardiovascular risk factors in obese children with relative growth hormone deficiency

Lipids in Health and Disease, 2018
Background Based on the sample of obese children with relative growth hormone deficiency (GHD), the objective of our study was to determine the effects of rhGH treatment on cardiovascular risk factors, including body mass index (BMI), lipid levels and ...
Shuang Liang, Jiang Xue, Guimei Li
doaj   +1 more source

Long-term response to recombinant human growth hormone therapy in Indian children with growth hormone deficiency

Indian Journal of Endocrinology and Metabolism, 2019
Background: Growth hormone deficiency (GHD) remains the most common indication for use of recombinant human growth hormone (rhGH) therapy in clinical practice.
Monita Gahlot, Alpesh Goyal, Arun K C. Singh, Viveka P Jyotsna, Nandita Gupta, Rajesh Khadgawat   +5 more
doaj   +1 more source

Growth Hormone Therapy in Children with Chronic Renal Failure

Eurasian Journal of Medicine, 2019
Growth is impaired in a chronic renal failure. Anemia, acidosis, reduced intake of calories and protein, decreased synthesis of vitamin D and increased parathyroid hormone levels, hyperphosphatemia, renal osteodystrophy and changes in growth hormone ...
Atilla Cayir, Celalettin Kosan
doaj   +1 more source

Parameters Used for Evaluation of the Response to Treatment with Recombinant Human Growth Hormone in Paediatric and Adult Populations in Poland: Review

Journal of Education, Health and Sport
Introduction and purpose  Recombinant human growth hormone (rhGH) therapy has been the standard treatment  for paediatric short stature for many years, and a therapeutic option for the replacement therapy of growth hormone deficiency in the post ...
Agata Kotkowiak, Mikołaj Łabuda, Agnieszka Szema , Jakub Sikora, Karolina Knychalska, Klaudia Królikowska, Aleksandra Słojewska, Teresa Sowińska, Oliwia Mentel, Adrianna Bogucka   +9 more
doaj   +1 more source

Heterozygous loss‐of‐function alleles associate the conserved 3′‐5′ exoribonuclease EXOSC10 with hypersensitivity to the anticancer drug 5‐fluorouracil

Molecular Oncology, EarlyView.
EXOSC10, an essential nuclear RNA exosome‐associated 3′‐5′ exoribonuclease, is inhibited by the anticancer drug 5‐fluorouracil (5‐FU), and EXOSC10 depletion increases 5‐FU sensitivity. The colon‐cancer variant EXOSC10S402T, located in a proteolysis motif, is stable and nuclear but nonfunctional in vivo.
Radhika Sain, Yann Le Page, Frédéric Percevault, Emmanuelle Becker, Luc Negroni, Almudena Fernandez, Marta Cantero, Diego Muñoz‐Santos, Lluís Montoliu, Cyrille Garnier, Michael Primig   +10 more
wiley   +1 more source

PEGylated Recombinant Human Growth Hormone Jintrolong® Exhibits Good Long-Term Safety in Cynomolgus Monkeys and Human Pediatric Growth Hormone Deficiency Patients

Frontiers in Endocrinology, 2022
Jintrolong® is a long-acting PEGylated recombinant human growth hormone (PEG-rhGH) developed for weekly injection in patients with pediatric growth hormone deficiency (PGHD). Although PEG modification of therapeutic proteins is generally considered safe,
Wei Wu, Juan Zhou, Chuandong Wu, Qian Zhou, Xiaoyu Li, Yanlin Zhang, Conglin Zuo, Jun Yin, Ling Hou, Shuyang Wang, Hongyang Gao, Tianhong Luo, Lei Jin, Enhong Zhong, Yingwu Wang, Xiaoping Luo   +15 more
doaj   +1 more source

Development of human monoclonal antibodies against TARM1 by yeast display

FEBS Open Bio, EarlyView.
Human monoclonal antibodies against TARM1 are generated by yeast display‐guided selection. These antibodies bind to soluble and cell‐surface forms of TARM1. Also, these antibodies exhibit agonistic activity in the NFAT‐GFP reporter assay, indicating that TARM1 signaling can be functionally modulated by antibodies and suggesting TARM1 as a potential ...
Rikio Yabe, Mayumi Saeki, Masaaki Hashiguchi, Sayaka Ono, Kazuhisa Aoki, Hidetaka Tanno   +5 more
wiley   +1 more source